Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer.
Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. · 2009
Read Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. by Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2696767.txt.
Introduction
Nilsson and colleagues reported in 2009 that urine carries tiny tumor parcels whose RNA could betray prostate cancer without a biopsy. Tumors shed exosomes, small bubbles packed with molecular cargo, and the prostate drains toward the urinary tract. The team asked whether two known prostate cancer RNA markers could be found in exosomes filtered from patients' urine.
Both markers were there. One, PCA-3, is already used clinically as a urine test. The second is a fused gene, TMPRSS2:ERG, formed when two genes break and rejoin wrongly, a signature found in many prostate tumors. Detecting cancer RNA in a cup of urine, rather than in tissue snipped from the gland, promises diagnosis and monitoring with far less pain and risk. The authors present it as proof of concept: exosome cargo mirrors the tumor that shed it.
Catalog record
| CREATOR | Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer By J Nilsson, J Skog, A Nordstrand, V Baranov, L Mincheva-Nilsson, X O Breakefield, A Widmark Published in: British Journal of Cancer DOI: 10.1038/sj.bjc.6605058 ABSTRACT Abstract Herein, we describe a novel approach in the search for prostate cancer biomarkers, which relies on the transcriptome within tumour exosomes. As a proof-of-concept, we show the presence of two known prostate cancer biomarkers, PCA-3 and TMPRSS2:ERG the in exosomes isolated from urine of patients, showing the potential for diagnosis and monitoring cancer patients status. Keywords: prostate cancer, prostasomes, tumour exosomes, biomarkers Prostate cancer (PCa) is the only one of the four solid tumour types, breast, lung and colorectal cancer, which has a clinical useful protein biomarker for diagnostics and follow-up after treatment. Prostate-specific antigen (PSA) has shown reasonable sensitivity for detection of incipient cancer and can also predict response to treatment (Freedland et al, 2005). One of the drawbacks with PSA is its low specificity, such that benign hyperplasic conditions can also be associated with a PSA increase (Catalona et al, 1994). Thus, additional PCa biomarkers are needed, especially the ones that give information about the severity of the disease and can predict high or low risk for future metastases. In this article, we evaluated a novel approach to find predictive markers for PCa, and analysed RNA in urine exosomes from PCa patients. Two types of microvesicles are present in prostate secretions: (1) prostasomes (150–500 nm), produced by prostatic ductal epithelial cells that are a normal component of seminal fluid and play a role in male fertility (Burden et al, 2006); and (2) exosomes, specialised nanovesicles (30–100 nm) with a cup-shaped morphology, actively secreted by a variety of normal and tumour cells. Elevated exosome secretion has been found in malignancy effusions, serum and urine from cancer patients (Mitchell et al, 2009). In addition, it was shown that exosomes released from a mast cell line (Valadi et al, 2007) and glioblastoma tumour cells (Skog et al, 2008) contain intact mRNA that can be transferred to recipient cells and therein translated into functional proteins (Skog et al, 2008). Certain RNA transcripts are enriched several 100-fold in the exosomes compared with the donor cells, supporting a specific packing mechanism (Skog et al, 2008). The exosomes lack essentially all of the ribosomal RNA, which represent ∼80% of the total RNA in cells, and thus contains mainly mRNAs and microRNAs (miRNAs). Therefore, exosomes are enriched in unique transcripts specific to tumour cells that may be below detection limit even in the tumour cells themselves (Skog et al, 2008; Taylor and Gercel-Taylor, 2008). In addition, individual PCa are often very heterogeneous in their phenotype, and a biopsy taken from one region of the tumour can have a distinct genotype from another region. Therefore, analysing the transcriptome in secreted PCa exosomes in urine has the advantages of being both noninvasive and informative as to the overall tumour malignancy status, including tumour-specific splice variants, mutations, and mRNA and miRNA levels known to be diagnostic for PCa. Other groups have shown that tumour cells shed into the urine after mild prostate massage can be used as an mRNA source for the discovery of tumour biomarkers (Hessels et al, 2007; Laxman et al, 2008). In this study we have taken this concept a step further to analyse the tumour exosome fraction in urine. Using a nested PCR-based approach, we were able to show that tumour exosomes carry genetic information specific for PCa, and as a proof-of-principle we used tumour exosomes to detect two PCa mRNA biomarkers, PCA-3 and TMPRSS2:ERG (Hessels et al, 2007; Laxman et al, 2008). This study supports the use of RNA in exosomes isolated from urine as diagnostic markers for PCa, and offers an alternative, sensitive and unique new type of PCa biomarkers. MATERIALS AND METHODS Sample acquisition and microvesicle preparation Samples were obtained after informed consent. Urine from the patients was collected before and after receiving prostate massage, except for patients with bone metastases where only a normal urine sample was collected. Detailed information about the patients is presented in Table 1. The microvesicular fraction was prepared by differential centrifugation. First, cells were pelleted at 500 g for 20 min at 10°C and discarded, and then additional cellular debris was removed by centrifugation at 16 000 g for 20 min at 10°C, followed by filtration through a 0.45 μm filter device (Millipore, Bedford, MA, USA). The microvesicles in the filtrate were then pelleted by ultracentrifugation (Beckman Coulter AB, Bromma, Sweden; Ti70 rotor) at 100 000 g for 90 min at 10°C. For electron microscopic studies, the microvesicles were additionally purified by ultracentrifugation in a 20 and 40% sucrose gradient and washed with filtered phosphate-buffered saline (PBS). [Table: Diagnostic T-stage, Gleason score, PSA levels (ng ml–1) before start of treatment] Electron microscopy To maximally concentrate the microvesicles, 15 μl drops in PBS were placed on 2% agarose. Formvar/carbon-coated glow-discharged nickel grids were placed on top of the drops and allowed to stand for 5–10 min to absorb excess fluid. The grids with adherent microvesicles were washed and fixed with 2% paraformaldehyde in PBS for 10 min. For negative staining, the grids were incubated on ice for 10 min with 25 μl drops of 1.9% methyl cellulose containing 0.3% uranyl acetate. Excess fluid was removed before examination with electron microscope. For immunoelectron microscopy, the microvesicles were incubated for 10 min in blocking solution (0.1 M glycine and 0.3% bovine serum albumin) and added to the grids. The microvesicles were incubated with anti-CD63 monoclonal antibodies (Fitzgerald laboratories, Concord, MA, USA) or with isotype-matched murine control antibodies (Dako A/S, DakoCytomation Norden, Glostrup, Denmark) as a negative control for 1 h. After washing, the grids were incubated with goat-anti-mouse secondary antibodies conjugated with 10 nm-sized gold particles (Sigma-Aldrich Sweden AB, Stockholm, Sweden) for 1 h. After washing and additional fixation in 2.5% glutaraldehyde, the grids were negatively stained as described above. Total RNA isolation, cDNA synthesis and nested PCR analysis Total RNA was extracted from the exosomal or prostasomal pellet and treated with DNase according to the manufacturer's recommendations (RNAqueous and TURBO-DNase, Ambion Inc., TX, USA), and later converted to cDNA (RETROscript, Ambion). Nested PCR was used to detect transcripts of the selected biomarkers. In brief, 1.5 μl of the cDNA product was amplified in a 15 μl reaction, using AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA, USA) with the F1/R1 primer set for 40 cycles, then 1.5 μl from the first PCR reaction were amplified with the F2/R2 primer set for another 40 cycles. Positive samples from the nested PCR reaction were then re-amplified from the first PCR reaction for a second time and digested with restriction enzymes to ensure correct products. The TMPRSS2:ERG PCR products were re-amplified with the F2/R2 primers, and the product was digested with Hae-II (New England Biolabs, lpswich, MA, USA) generating two distinct bands of 54 bp and 68 bp; the PCA-3 PCR products were re-amplified with the F1/R2 primers and digested with Sca-I (New England Biolabs), generating two fragments of 90 bp and 62 bp. Each gene product was also cloned into a cloning vector (pCR4-TOPO, Invitrogen Ltd, Paisley, UK) and sequenced (BigDye, Applied